News

We’re proud to share a new scientific publication by our CEO, Prof. Matthias Günther!
His latest article in Magnetic Resonance in Medicine describes gammaSTAR, a powerful, vendor-independent MR sequence development platform with real-time feedback capabilities.

What makes gammaSTAR unique?
The framework enables:

• Rapid development of advanced MR sequences using a modular architecture (Python, Lua, vendor-specific drivers)
• Real-time feedback integration for applications like prospective motion correction
• Seamless execution of complex sequences (e.g., pCASL GRASE, 3D radial UTE) without long preparation times
• High reproducibility across scanners at 1.5T and 3T, with image quality comparable to leading vendors

In vivo results show:

• Excellent agreement in image contrast and ADC values
• Significant reduction in motion artifacts (voxel displacement reduced from 1.63 mm to 0.37 mm with correction)
• Compatibility with standard vendor reconstruction pipelines

This important work is part of our SIMAB project, a collaboration with @Fraunhofer MEVIS, funded by the German Federal Ministry of Education and Research. Together, we are developing a vendor-agnostic MR sequence framework to enable consistent, high-quality imaging in multicenter clinical trials—regardless of scanner type.

At mediri, we are committed to making imaging in clinical trials more reliable, reproducible, and patient-centric.
– Innovation through collaboration
– Imaging that connects
– Trust in every scan

Read the full publication here:
👉 https://pubmed.ncbi.nlm.nih.gov/40391628/

Sometimes, medical images want to be seen in a different light …

On this International Clinical Trials Day, we appreciate the progress made in clinical research – and the vital role that advanced medical imaging plays in shaping tomorrow’s therapies.

As imaging CRO, we specialize in cutting-edge imaging solutions that support clinical trials across the globe. From AI-assisted analysis support to centralized image read and data management, our work ensures that imaging biomarkers are not just captured – but truly understood.

Clinical trials are the backbone of medical innovation. By integrating precise, high-quality imaging into study workflows, we help researchers gain deeper insights, accelerate decision-making, and ultimately bring life-changing treatments to patients faster.
Together, we’re shaping the future of medicine! 

This week our three PhD researchers, Yaqeen Ali, Tewele Weletnsea Tareke and Alessio Fiorin from the BosomShield Project met with their mentor Prof. Dr. Johannes Gregori at Darmstadt University of Applied Sciences for an inspiring exchange of ideas.

We are proud to be part of this cutting-edge European research initiative, and even more excited to see the energy and expertise these young scientists bring to the table. Their fresh perspectives are truly inspiring!

Their visit provided a fantastic opportunity for in-depth scientific exchange, fostering collaboration, innovation, and stronger connections within the AI-driven breast cancer diagnostics community. 

Medical imaging plays an increasingly vital role in clinical research – and we’re proud to be leading the way with innovative imaging solutions.

Joins us to discuss this and other topics at the 19th Clinical Trials Strategic Summit (CTSS) 2025 in Munich, where our COO, Dr. Julia Müller, will represent us.

At mediri, we specialize in advanced medical imaging solutions that support clinical trials from early-phase research to multi-center studies. Our expertise spans image data management, centralized image reading, and AI-assisted analysis, helping to ensure precision, consistency, and regulatory compliance in clinical research.
The CTSS summit is a fantastic opportunity to exchange ideas, explore innovations, and shape the future of clinical trials together.

We’re looking forward to insightful discussions and new collaborations.
Let’s connect in Munich!

We’ve reached 1500 followers! 

We are incredibly grateful for your support and thrilled to have such an amazing community. Thank you for being a part of our journey! We look forward to achieving even greater things with you by our side!

mediri is your dedicated partner for efficient and reliable imaging studies. With extensive experience in clinical studies, cutting-edge software, and imaging expertise, we provide comprehensive solutions from site management and quality control to central evaluation. Our cloud platform, mTRIAL, ensures seamless data exchange, top-notch data security in Germany, and AI-supported workflows tailored to your study. We drive clinical studies forward and bring new diagnostic techniques to patients, fueled by scientific curiosity and interdisciplinary project experience.

We are delighted to have Tewele Weletnsea TAREKE , Ph.D. student for the BosomShield project with us for the next four weeks, enriching our mediri research team. Tewele is here as part of the BosomShield project, working on advancing AI-based radiomics and making meaningful contributions to the future of precision oncology.
Welcome aboard, Tewele! We look forward to the innovative insights and progress you’ll bring to our team. 

We are thrilled about the market approval of Lecanemab in the EU, marking a promising breakthrough for millions affected by Alzheimer’s disease. Early detection is crucial, and in this field, our ASL team is at the forefront of research. Upcoming observational studies can be supported by our cutting-edge technology, which can non-invasively monitor the course of the disease.

Arterial Spin Labeling (ASL) represents a modern MRI technique for measuring regional brain perfusion and permeability by modifying the magnetization of blood water protons to serve as natural tracers. This method is entirely non-invasive, eliminating the need for ionizing radiation or external contrast agents.

The non-invasive nature of ASL provides numerous benefits for clinical research: it allows for repeated cerebral blood flow (CBF) measurements as often as needed and is suitable for use in vulnerable groups, such as patients with renal failure, elderly individuals or Alzheimer’s patients.

Brain Perfusion & Parkinson’s: A Vital Connection

Parkinson’s disease (PD) is a progressive neurodegenerative disorder, and understanding brain blood flow is key to improving diagnosis and treatment. Arterial Spin Labeling (ASL) MRI, a non-invasive perfusion imaging technique, provides valuable insights by measuring cerebral blood flow.

Early Detection – Identifies perfusion changes before significant symptoms appear.
Tracking Disease Progression – Monitors blood flow reductions in affected brain regions.
Optimizing Treatment – Helps assess therapy effectiveness and personalize care.
Advancing Research – Aids in drug development and deeper understanding of PD pathology.

ASL MRI is revolutionizing how we detect, monitor, and treat Parkinson’s, paving the way for more precise and effective interventions.

At mediri GmbH, we support you with sophisticated yet easy-to-use ASL image analysis tools, including specialized ASL sequences that can measure exchange time. Our services cover all aspects of ASL imaging.
As a one-stop-shop, we provide comprehensive evaluation services. We specialize in clinical trials that demand precise image data acquisition and quality assurance. Our services include image collection, quality checks, site support, and project management. Perfect for clinical trials requiring longitudinal imaging data or centralized reviews.

On this World Health Day, we emphasize the need for quality healthcare for women before, during, and after pregnancy and childbirth. Women’s health is a cornerstone of thriving families and communities.

At mediri, we take pride in being an employer that champions the health and well-being of our female employees. We are dedicated to creating a supportive workplace that nurtures their health.

Let’s unite in our efforts to ensure every woman receives the care she deserves. Together, we can create a healthier world!

Arterial Spin Labeling (ASL) represents a modern MRI technique for measuring perfusion, which modifies the magnetization of blood water protons to serve as natural tracers.
This method is entirely non-invasive, eliminating the need for ionizing radiation or external contrast agents.
The non-invasive nature of ASL provides numerous benefits for clinical research: it allows for repeated cerebral blood flow (CBF) measurements as often as needed and is suitable for use in vulnerable groups, such as patients with renal failure or pediatric patients.

Why It Matters: ASL offers a safe and effective way to measure cerebral perfusion, making it ideal for various clinical applications.

Have you heard about ASL before? Share your thoughts and experiences with us!